| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:2148-2153.)
© 2006 American Heart Association, Inc.
Interventional Cardiology |
From Asan Medical Center (Y.-H.K., S.-W.P., S.-W.L., D.-W.P., S.-C.Y., C.W.L., M.-K.H., S.-J.P.), University of Ulsan College of Medicine, Seoul, Korea; Chonbuk National University Hospital (H.-S.K., J.-K.K.), Jeonju, Korea; Chungnam National University Hospital (J.-H.P., J.-H.L., S.W.C., I.-W.S.), Daejeon, Korea; Soonchunhyang University Bucheon Hospital (Y.H.C., N.-H.L.), Soonchunhyang, Korea; and Pusan National University Hospital (J.H.K., K.-J.C.), Busan, Korea.
Correspondence to Seung-Jung Park, MD, PhD, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul, 138-736, Korea. E-mail sjpark{at}amc.seoul.kr
Received September 22, 2006; revision received October 6, 2006; accepted October 13, 2006.
Background Outcomes remain relatively unfavorable for stent-based coronary intervention of lesions with long diseased segments. This study compared sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) for long coronary lesions.
Methods and Results The present randomized, multicenter, prospective study compared the use of long (
32 mm) SES with PES in 500 patients with long (
25 mm) native coronary lesions. The primary end point of the trial was the rate of binary in-segment restenosis according to follow-up angiography at 6 months. The SES and PES groups had similar baseline characteristics. Lesion length was 33.9±11.6 mm in the SES group and 34.5±12.6 mm in the PES group (P=0.527). The in-segment binary restenosis rate was significantly lower in the SES group than in the PES group (3.3% versus 14.6%; relative risk 0.23; P<0.001). In-stent late loss of lumen diameter was 0.09±0.37 mm in the SES group and 0.45±0.55 mm in the PES group (P<0.001). In patients with restenoses, a pattern of focal restenosis was more common in the SES group than in the PES group (100% versus 53.3%, P=0.031). Consequently, SES patients had a lower rate of target-lesion revascularization at 9 months (2.4% versus 7.2%, P=0.012). The incidence of death (0.8% in SES versus 0% in PES, P=0.499) or myocardial infarction (8.8% in SES versus 10.8% in PES, P=0.452) at 9 months of follow-up was not statistically different between the 2 groups.
Conclusions For patients with long native coronary artery disease, SES implantation was associated with a reduced incidence of angiographic restenosis and a reduced need for target-lesion revascularization compared with PES implantation.
This article has been cited by other articles:
![]() |
S.-J. Park and Y.-H. Kim Current Status of Percutaneous Coronary Intervention With Drug-Eluting Stents in Asia Circulation, December 16, 2008; 118(25): 2730 - 2737. [Full Text] [PDF] |
||||
![]() |
S.-W. Lee, S.-W. Park, Y.-H. Kim, S.-C. Yun, D.-W. Park, C. W. Lee, M.-K. Hong, K.-S. Rhee, J. K. Chae, J.-K. Ko, et al. A Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting Stent Implantation in Patients With Diabetes Mellitus J. Am. Coll. Cardiol., August 26, 2008; 52(9): 727 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Billinger, J. Beutler, K. R. Taghetchian, A. Remondino, P. Wenaweser, S. Cook, M. Togni, C. Seiler, C. Stettler, F. R. Eberli, et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients Eur. Heart J., March 2, 2008; 29(6): 718 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Galloe, L. Thuesen, H. Kelbaek, P. Thayssen, K. Rasmussen, P. R. Hansen, N. Bligaard, K. Saunamaki, A. Junker, J. Aaroe, et al. Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial JAMA, January 30, 2008; 299(4): 409 - 416. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schomig, A. Dibra, S. Windecker, J. Mehilli, J. Suarez de Lezo, C. Kaiser, S.-J. Park, J.-J. Goy, J.-H. Lee, E. Di Lorenzo, et al. A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1373 - 1380. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Kereiakes The Emperor's New Clothes: Another Cypher Versus Taxus Post-Hoc Meta-Analysis J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1381 - 1385. [Full Text] [PDF] |
||||
![]() |
N. M M Pires, D. Eefting, M. R de Vries, P. H A Quax, and J W. Jukema Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries Heart, August 1, 2007; 93(8): 922 - 927. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., July 17, 2007; 50(3): 270 - 285. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |